Reuters | AstraZeneca's Crestor fails to show significant improvement over Lipitor The Pharma Letter There was a big disappointment for Anglo-Swedish drug major AstraZeneca (LSE: AZN) on Friday, when it revealed results of a new study that failed to show its drug Crestor (rosuvastatin) was a significant improvement over US behemoth Pfizer's (NYSE: ... Crestor fails to outshine Lipitor Rosuvastatin Fails to Best Atorvastatin in IVUS Study of Atherosclerosis ... |
No comments:
Post a Comment